短期177Lu-PSMA放射配体治疗在高瘤负荷mHSPC中的显著疗效
本文报告一例69岁新发高瘤负荷转移性激素敏感性前列腺癌(mHSPC)患者,初始PSA 433.75 ng/mL,伴广泛骨及淋巴结转移。经戈舍瑞林、阿比特龙及醋酸环丙孕酮雄激素剥夺治疗后PSA降至44.29 ng/mL,随后接受3周期177Lu-PSMA放射配体治疗,获近完全生化缓解(PSA 0.15 ng/mL)并骨痛消失;9个月随访99mTc-PSMA显像示转移灶完全消退。
要点
- 高瘤负荷mHSPC经3周期177Lu-PSMA治疗可达近完全生化缓解
- 治疗后骨痛消失,随访99mTc-PSMA示转移灶完全消退
- 提示早期177Lu-PSMA治疗在高瘤负荷mHSPC中可能有效且安全
核心结论
- 早期177Lu-PSMA治疗在高瘤负荷mHSPC中显示潜在疗效与安全性,可能有助于优化激素治疗结局。
研究设计与样本
- 个案报告:1例69岁新发高瘤负荷mHSPC患者。
主要发现
- 雄激素剥夺治疗后PSA由433.75 ng/mL降至44.29 ng/mL。
- 3周期177Lu-PSMA后PSA降至0.15 ng/mL,达近完全生化缓解,骨痛消失。
- 9个月随访99mTc-PSMA示转移病灶完全消退。
关键数值与推荐
- 治疗方案为戈舍瑞林、阿比特龙及醋酸环丙孕酮雄激素剥夺治疗后行3周期177Lu-PSMA放射配体治疗。
临床怎么用
- 对高瘤负荷mHSPC可考虑早期联合177Lu-PSMA治疗,并以PSA及PSMA显像随访疗效。
局限性
- 为单例个案报告,证据级别有限,结论需更大样本研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We report a 69-year-old man with de novo high-volume metastatic hormone-sensitive prostate cancer (mHSPC) presenting with PSA 433.75 ng/mL and widespread skeletal and nodal metastases. Androgen-deprivation therapy with goserelin, abiraterone, and cyproterone acetate reduced PSA to 44.29 ng/mL. He subsequently received 3 cycles of 177 Lu-PSMA radioligand therapy, achieving a near-complete biochemical response (PSA 0.15 ng/mL) and resolution of bone pain. Nine-month follow-up 99m Tc-PSMA demonstrated complete regression of metastatic lesions. This case highlights the potential efficacy and safety of early 177 Lu-PSMA therapy in high-volume mHSPC, suggesting a role for optimizing hormonal therapy outcomes.
引用
- Rezaei Borujerdi N, Saber Tanha A, Elahifard H, et al. Exceptional Response to Short-course 177 Lu-PSMA Radioligand Therapy in a Patient With Metastatic Hormone-sensitive Prostate Cancer. Clin Nucl Med. 2026. PMID: 42007836. doi:10.1097/RLU.0000000000006452
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。